Cabrera Analía Mónica, Fain Humberto, Fain Bruno, Muniategui Julieta, Buiras Viviana María, Galicchio Santiago, Cacchia Pedro Alberto, Retamero Mirta, Ocampo Rosana Patricia, Porto Mariela Betina
Hospital de Niños Dr. Víctor J. Vilela.
Hospital de Niños Victor J. Vilela.
Nutr Hosp. 2021 Dec 9;38(6):1144-1148. doi: 10.20960/nh.03172.
Background: the ketogenic diet (CD) is an established, effective non-pharmacological treatment for refractory epilepsy in childhood. Aim: the objective of this study was to compare the efficacy, the presence of undesirable effects, and adherence between the classic ketogenic diet (DCC) and the modified Atkins diet (DAM). Materials and methods: a retrospective and comparative investigation was carried out to evaluate the medical records of all the patients who started treatment with a ketogenic diet by the same team between 2008 and 2018. In all, 57 patients were started on a DAM diet and 19 patients were given a DCC diet. Results: it was observed that both the Atkins and the classic diets were equally effective (approximately, 80 %; p = 0.252). Regarding adherence, there was a significantly higher percentage of adherence to the Atkins diet than to the classic diet (p = 0.018). Fewer adverse effects were observed with DAM than with DCC (p = 0.012). In all, 21 % of patients under DAM had unfavorable effects (12/57), while 52.63 % of patients on DCC had complications (10/19). Conclusion: a comparable effectiveness in terms of crisis control was found between DAM and DCC. However, DAM exhibits a much better adherence than DCC, and its undesirable effects are milder, less common. That is why, according to other works, it is likely that DAM should be first-choice for patients with refractory epilepsy in a large percentage of cases.
生酮饮食(CD)是一种已确立的、有效的儿童难治性癫痫非药物治疗方法。目的:本研究的目的是比较经典生酮饮食(DCC)和改良阿特金斯饮食(DAM)的疗效、不良反应的发生情况及依从性。材料与方法:进行了一项回顾性比较研究,以评估2008年至2018年间同一团队开始采用生酮饮食治疗的所有患者的病历。共有57例患者开始采用DAM饮食,19例患者采用DCC饮食。结果:观察到阿特金斯饮食和经典饮食同样有效(约80%;p = 0.252)。关于依从性,阿特金斯饮食的依从率显著高于经典饮食(p = 0.018)。与DCC相比,DAM观察到的不良反应更少(p = 0.012)。总体而言,采用DAM的患者中有21%(12/57)出现不良影响,而采用DCC的患者中有52.63%(10/19)出现并发症。结论:发现DAM和DCC在控制发作方面具有相当的有效性。然而,DAM的依从性比DCC好得多,其不良反应更轻微、更少见。正因如此,根据其他研究,在大多数情况下,DAM很可能应成为难治性癫痫患者的首选。